Insulin aspart-szjj: An Insulin aspart Biosimilar

DeclarationsFunding The preparation of this review was not supported by any external fundingAuthorship and Conflict of interest During the peer review process, the manufacturer of insulin aspart-szjj, Sanofi, was offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit. A. McGuigan is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.Additional information about this Adis Drug Review can be found here.AbstractInsulin aspart‑szjj (MERILOG™) is a biosimilar of the reference rapid-acting insulin analog, insulin aspart, and is approved to improve glycemic control in adult and pediatric patients with diabetes mellitus, the same indication for which reference insulin aspart is approved. The pharmacodynamic and pharmacokinetic similarity of insulin aspart‑szjj, US-, and EU-sourced reference insulin aspart has been shown in patients with type 1 diabetes. Insulin aspart‑szjj demonstrated clinical efficacy similar to that of reference insulin aspart in patients with type 1 or type 2 diabetes and was generally well tolerated in this population. The tolerability, safety, and immunogenicity profiles of insulin aspart‑szjj were similar to those of reference insulin aspart. The role of insulin aspart in the management of diabetes mellitus is well established, and insulin aspart‑szjj provides an effective biosimilar alternative for patients with diabetes mellitus requiring reference insulin aspart.© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2025